Evidence map›Paper›PMID 35004283›Full record

ArticleFrontiers in oncology2021

m

Jiawei Chen, Shuchen Sun, Leihao Ren, Lingyang Hua, Daijun Wang, Qing Xie, Hans-Georg Wirsching, Jiaojiao Deng, Michael Weller, Ye Gong

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Jiawei ChenDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Shuchen SunDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Leihao RenDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Lingyang HuaDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Daijun WangDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Qing XieDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Hans-Georg WirschingDepartment of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
Jiaojiao DengDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Michael WellerDepartment of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
Ye GongDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Fudan University · CNHuashan Hospital · CNUniversity Hospital of Zurich · CHUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMeningiomas are the most common primary intracranial tumors in adults. According to the 2021 World Health Organization (WHO) classification of central nervous system tumors, approximately 80% of meningiomas are WHO grade 1, that is, histopathologically benign, whereas about 20% are WHO grade 2 or grade 3, showing signs of atypia or malignancy. The dysregulation of N6-methylation (m

methodsWe evaluated the m

resultsTwo meningioma clusters were identified based on the expression of 19 m

conclusionm

Indexed as

immune infiltrationm6Ameningiomamolecular subtypeWGCNA

Identifiers

PMID35004283
PMCPMC8727752
OpenAlexW4200300145

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.